Overview
Introduction
With CML’s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis’ Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market.
Scope
Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis.
Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010.
Assesses the CML market’s future based on the attention that Gleevec has provided and where the attention will likely move in the future.
Report Highlights
Genta/Aventis’ Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents.
Reasons to Purchase
Access insights into the developmental gains available through CML and into the path to a successful revenue stream.
Identify how targeting CML can provide significant sales gains through off-label usage in AML.
Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development.
Report Highlights
Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position.
The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias.
INTRODUCTION TO CHRONIC MYELOID LEUKEMIA
A description of chronic myeloid leukemia (CML), its market and historic therapies
GLEEVEC CASE STUDY
Analysis of the developmental and market strategies that have contributed to the success of Gleevec
CML PIPELINE
Overview of the key compounds in development for CML, with forecasts to 2010
- Decitabine
- Genasense
- PEG-Intron
THE FUTURE CML MARKET
An assessment of the dynamics of the CML market
DATASETS
Table 1: Current gold-standard therapies for CML, 2002
Table 2: Quarterly sales data for Gleevec since launch
Table 3: Global forecasts for Gleevec, 2002-2010
Table 4: Late-stage developmental compounds for CML, 2002
Table 5: The number of compounds in development for the differing leukemia indications, 2002
Table 6: Global forecasts for decitabine, 2004-2010
Table 7: Global forecasts for Genasense, 2004-2010
Figure 1: The typical progression of CML
Figure 2: Gleevec’s proposed mechanism of action
Figure 3: Comparison of the niche and major markets, and the benefits that each hold
Figure 4: The underlying strategies that Novartis has undertaken to market Gleevec
Figure 5: Key factors in the relative success of decitabine
Figure 6: Key factors in the relative success of Genasense
Figure 7: Key factors in the relative success of PEG-Intron
Last Name: 